

Balaxi Pharmaceuticals Limited

September 27, 2022

To
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai - 400051

NSE Symbol: BALAXI

Subject: Summary of proceedings of the Extraordinary General Meeting of the Company held on Tuesday, September 27, 2022.

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the summary of proceedings of the Extraordinary General Meeting (EGM) of the Members of the Company held on Tuesday, September 27, 2022, at 10.30 A.M. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM).

The proceedings of the EGM will also be hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,
For **Balaxi Pharmaceuticals Limited**

Ashish Maheshwari
(Managing Director)
DIN: 01575984

Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

(Formerly known as Balaxi Ventures Limited)

SUMMARY OF PROCEEDINGS OF THE EXTRAORDINARY GENERAL MEETING OF BALAXI PHARMACEUTICALS LIMITED

The Extraordinary General Meeting (EGM) of the Members of Balaxi Pharmaceuticals Limited (the Company) was held on Tuesday, September 27, 2022, at 10.30 A.M. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM), in compliance with General Circular No. 2/2022 and 19/2021, other circulars issued by the Ministry of Corporate Affairs (MCA) and Circular SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated May 13, 2022 issued by the Securities and Exchange Board of India (SEBI) (hereinafter collectively referred to as the Circulars) along with applicable provisions of the Companies Act, 2013.

Mr. Ashish Maheshwari, Chairman of the Board, took the chair and conducted the proceedings of the EGM.

Mr. Amol Mantri, Chief Financial Officer, welcomed the members to the EGM. As there was requisite quorum present, with the permission of the Chairman, he called the meeting to order. He then introduced the members of the Board, the Statutory Auditor and the Secretarial Auditor. Four Directors were present at the EGM, including the Chairman of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee.

Mr. Amol Mantri, Chief Financial Officer, informed the members that the certificate from M/s BVR & Associates Company Secretaries LLP certifying that the preferential issue is being made in accordance with the requirements of Chapter V of SEBI ICDR Regulations were available for inspection electronically. Members, if interested, in inspecting the same, were requested to send an email to secretarial@balaxi.in. He also informed that as the EGM was conducted through VC/ OAVM, the facility for appointment of proxies by the members is not applicable.

He further informed the members that:

- a) The Company had provided remote e-voting facility to the members to exercise their vote in respect of business proposed in the notice of EGM through Central Depository Services (India) Limited (CDSL). The remote e-voting commenced on September 22, 2022 at 09:00 A.M. (IST) and ended on September 26, 2022 at 05:00 P.M. (IST).
- b) The Members who had not exercised their vote through remote e-voting are requested to cast their vote during the meeting.
- c) BVR & Associates Company Secretaries LLP were appointed as the Scrutinizer for remote e-voting and e-voting done during the EGM.

He then requested the Chairman to address the members. Chairman welcomed and addressed the Members.

Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

(Formerly known as Balaxi Ventures Limited)

Balaxi Pharmaceuticals Limited

Mr. Amol Mantri, Chief Financial Officer, with the concurrence of all the members present informed that the notice convening the EGM of the Company was taken as read and tabled all resolutions as per the notice of EGM for e-voting at the meeting.

Thereafter, Members who had registered as speakers were invited one by one to pose their views/remarks or queries. Mr. Ashish Maheshwari, Chairman, addressed the queries of the members raised during the meeting.

The following items were put to vote through remote e-voting and e-voting at the EGM:

Special Business(es)

- 1) To consider and approve the issuance of warrants convertible into Equity Shares of the Company on a preferential basis.
- 2) To consider and approve the issuance of Equity Shares of the Company on a preferential basis.

Chairman thanked the members for joining the meeting through VC/ OAVM. He once again requested members who have not exercised their vote through remote e-voting to cast their vote through e-voting facility which will remain open for 15 minutes after the conclusion of the EGM.

The meeting concluded at 11:15 A.M. (IST) (including time allowed for e-voting at the EGM).

This is for your information and records.

Yours Faithfully,
For **Balaxi Pharmaceuticals Limited**

Ashish Maheshwari
(Managing Director)
DIN: 01575984

Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

(Formerly known as Balaxi Ventures Limited)